#India #Bengaluru #Denosumab #Biosimilars #Biocon Biologics

Biocon Biologics Receives Positive Opinions for Biosimilar Denosumab

Biocon Biologics Ltd (BBL) is making headlines as it recently announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued favorable opinions regarding its biosimilar candidates for Denosumab. This news could pave the way for enhanced health solutions related to bone health in Europe.

The two biosimilars in question, Vevzuo® and Denosumab BBL (the brand name is still under approval), are recommended for various therapeutic indications crucial for bone health. The positive opinions stem from detailed assessments carried out by the CHMP, which included analyzing clinical study outcomes showcasing the comparability of these biosimilars in terms of pharmacokinetics, safety, efficacy, and immunogenicity when compared to the reference product.

The Vevzuo® biosimilar aims to prevent bone-related complications in adult cancer patients, particularly those with advanced stages involving the skeletal system. In addition, the Denosumab BBL variant targets osteoporosis treatment in postmenopausal women and addresses bone loss in high-risk men undergoing hormone-ablation treatments, alongside patients on long-term systemic glucocorticoids leading to bone loss.

As the CHMP's recommendations are considered, the European Commission will review these opinions. Following this review, detailed information about the approved indications and usage will be disseminated via the product characteristics summary (SmPC) and European Public Assessment Reports (EPAR), which will be available in all official EU languages. Until the European Commission grants a marketing authorization, however, these innovative biosimilars will not be available for use across the EU.

About Biocon Biologics

Biocon Biologics Ltd., as a subsidiary of Biocon Ltd, stands out as a global leader in biosimilars. The company focuses on making high-quality biosimilars accessible to a broader patient population at affordable prices. Utilizing advanced science, innovative technology platforms, and top-quality manufacturing systems, Biocon Biologics aims to reduce the costs of biological therapies while improving healthcare outcomes.

In this ambitious pursuit, Biocon Biologics has successfully integrated the global biosimilar operations of its longstanding partner, Viatris. This integration signifies a significant step in enhancing its value creation journey. Biocon Biologics has launched eight biosimilars across pivotal emerging and mature markets, including the United States, Europe, Australia, Canada, and Japan. Additionally, the company boasts a robust pipeline of 20 biosimilars in therapeutic areas such as diabetes, oncology, immunology, and ophthalmology, alongside other non-communicable diseases.

Biocon also champions numerous ‘firsts’ in the biosimilars industry and demonstrates a commitment to environmental, social, and governance (ESG) principles, prioritizing patient well-being, global health initiatives, and environmental sustainability, all while aligning with the United Nations’ Sustainable Development Goals.

For more information and updates, visit www.bioconbiologics.com and follow them on social media channels like X (formerly Twitter) and LinkedIn.

In sum, Biocon Biologics’ advancements in biosimilars hold the promise of improving patient outcomes and healthcare accessibility, especially for conditions affecting bone health. As they move forward with regulatory processes in Europe, the healthcare community watches closely to see how these biosimilars will impact treatment protocols and patient lives across the continent.